Our Mission

The laboratory is interested in addressing basic and translational questions at the interface of RNA biology, hematopoiesis, immunology, and cancer with the goal of improving human health.

Based on recent work using therapeutic modulation of RNA splicing to enhance anti-tumor immunity, there are two related domains of work. These revolve around studies of RNA processing in the context of (1) regulating leukocyte development and function (2) cancer immunotherapy.

 
 

Our Laboratory

The lab is located in the Center for Clinical Sciences Research (CCSR) building in the heart of Stanford Medical School in sunny Palo Alto.

 

 

Our members

Sydney Lu, M.D. Ph.D.

Principal Investigator

Sydney Lu is a physician-scientist who leads a research group at Stanford Medical School, Division of Hematology, Department of Medicine.

 

We are hiring:

  • Postdoctoral fellow

  • Life Sciences Research Professional

  • Graduate research assistant

 

Our latest publications

 

  • Lu SX, de Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, Knorr DA, Greenbaum B, Elhanati Y, Hogg SJ, Chow A, Ghosh A, Xie A, Zmarin D, Cui D, Erickson C, Singer M, Cho H, Wang E, Lu B, Durham BH, Shah H, Chowell D, Gabel AM, Shen Y, Liu J, Jin J, Rhodes MC, Taylor RE, Molina H, Wolchok J, Merghoub T, Diaz Jr. LA, Abdel-Wahab O, Bradley RK. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell 2021 Jul 22;184(15):4032-4047.e31. DOI: 10.1016/j.cell.2021.05.038

 

  • Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, Mailankody S, Lesokhin A, Shah U, Lu S*, Patel D, Derkach A, Wilkins C, Korde N. Comparison of Venous Thromboembolism Incidence in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide, Dexamethasone (RVD) or Carfilzomib, Lenalidomide, Dexamethasone (KRD) with Aspirin or Rivaroxaban Thromboprophylaxis. British J. Hematol. 2021, in press. DOI: 10.1111/bjh.17772